Cargando…
995. Safety and Efficacy of F/TAF and F/TDF for PrEP in DISCOVER Participants Taking F/TDF for PrEP at Baseline
BACKGROUND: DISCOVER is an ongoing trial comparing emtricitabine plus tenofovir alafenamide (F/TAF) or tenofovir disoproxil fumarate (F/TDF) for HIV pre-exposure prophylaxis (PrEP). DISCOVER included some participants already taking F/TDF for PrEP at baseline (BL) creating a unique opportunity to st...
Autores principales: | Campbell, Thomas, Clarke, Amanda, Trottier, Benoit, Carter, Christoph C, Shao, Yongwu, Ebrahimi, Ramin, Das, Moupali, Brainard, Diana M, Gladstein, Jay |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777480/ http://dx.doi.org/10.1093/ofid/ofaa439.1181 |
Ejemplares similares
-
1288. Bone Safety Outcomes with F/TAF vs. F/TDF for PrEP in the DISCOVER Trial
por: Wohl, David, et al.
Publicado: (2019) -
1962. Renal Outcomes for Participants Taking F/TAF vs. F/TDF for HIV PrEP in the DISCOVER Trial
por: Mills, Anthony, et al.
Publicado: (2019) -
866. Adherence to F/TDF for PrEP in Dried Blood Spots and HIV Infection Rates: A Pooled Analysis of Global PrEP Studies
por: Liu, Albert, et al.
Publicado: (2021) -
How safe is TDF/FTC as PrEP? A systematic review and
meta-analysis of the risk of adverse events in 13 randomised trials of PrEP
por: Pilkington, Victoria, et al.
Publicado: (2018) -
The importance of PrEP persistence in preventing HIV infections on PrEP
por: Spinelli, Matthew A, et al.
Publicado: (2020)